Focused On-demand Library for U4/U6 small nuclear ribonucleoprotein Prp4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O43172

UPID:

PRP4_HUMAN

Alternative names:

PRP4 homolog; U4/U6 snRNP 60 kDa protein; WD splicing factor Prp4

Alternative UPACC:

O43172; O43445; O43864; Q5T1M8; Q96DG2; Q96IK4

Background:

The U4/U6 small nuclear ribonucleoprotein Prp4, also known as PRP4 homolog, U4/U6 snRNP 60 kDa protein, and WD splicing factor Prp4, is integral to pre-mRNA splicing. As a component of the U4/U6-U5 tri-snRNP complex, it plays a pivotal role in spliceosome assembly and the formation of the precatalytic spliceosome (spliceosome B complex).

Therapeutic significance:

Retinitis pigmentosa 70, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field, is linked to mutations affecting Prp4. Understanding the role of U4/U6 small nuclear ribonucleoprotein Prp4 could open doors to potential therapeutic strategies for this condition.